These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 30485777)
21. Validation of New Signal Detection Methods for Web Query Log Data Compared to Signal Detection Algorithms Used With FAERS. Colilla S; Tov EY; Zhang L; Kurzinger ML; Tcherny-Lessenot S; Penfornis C; Jen S; Gonzalez DS; Caubel P; Welsh S; Juhaeri J Drug Saf; 2017 May; 40(5):399-408. PubMed ID: 28155198 [TBL] [Abstract][Full Text] [Related]
22. The new Sentinel Network--improving the evidence of medical-product safety. Platt R; Wilson M; Chan KA; Benner JS; Marchibroda J; McClellan M N Engl J Med; 2009 Aug; 361(7):645-7. PubMed ID: 19635947 [No Abstract] [Full Text] [Related]
23. FDA reporting program is key to safety information. Young D Am J Health Syst Pharm; 2002 Dec; 59(23):2279, 2284, 2289. PubMed ID: 12489365 [No Abstract] [Full Text] [Related]
24. [Evaluation of the Association of Hand-Foot Syndrome with Anticancer Drugs Using the US Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) Databases]. Sasaoka S; Matsui T; Abe J; Umetsu R; Kato Y; Ueda N; Hane Y; Motooka Y; Hatahira H; Kinosada Y; Nakamura M Yakugaku Zasshi; 2016; 136(3):507-15. PubMed ID: 26935094 [TBL] [Abstract][Full Text] [Related]
25. Reporting of adverse drug events: a key to postmarketing drug safety. Rheinstein PH Am Fam Physician; 1992 Sep; 46(3):873-4. PubMed ID: 1514478 [No Abstract] [Full Text] [Related]
26. Drug-safety pilot makes the grade. Ledford H Nature; 2014 Sep; 513(7519):472. PubMed ID: 25254456 [No Abstract] [Full Text] [Related]
27. FDA guidance document on monitoring delayed adverse events a good first start. Williams DA Mol Ther; 2005 Dec; 12(6):991-2. PubMed ID: 16271514 [No Abstract] [Full Text] [Related]
28. How many deaths occur annually from adverse drug reactions in the United States? Chyka PA Am J Med; 2000 Aug; 109(2):122-30. PubMed ID: 10967153 [TBL] [Abstract][Full Text] [Related]
29. Drug review and postmarketing surveillance programs are sound, but systems approach to risk management is needed, says FDA. Miller JL Am J Health Syst Pharm; 1999 Jul; 56(13):1294,6. PubMed ID: 10683122 [No Abstract] [Full Text] [Related]
30. Adverse drug reactions and reporting. Witte R Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100 [No Abstract] [Full Text] [Related]
31. The role of databases in drug postmarketing surveillance. Rodriguez EM; Staffa JA; Graham DJ Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586 [TBL] [Abstract][Full Text] [Related]
32. FDA Encourages Reporting of Tobacco Product Adverse Experiences. Retzky SS Chest; 2016 Dec; 150(6):1169-1170. PubMed ID: 27938736 [No Abstract] [Full Text] [Related]
39. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety. Qato DM; Alexander GC JAMA; 2011 Oct; 306(14):1595-6. PubMed ID: 21990303 [No Abstract] [Full Text] [Related]
40. A curated and standardized adverse drug event resource to accelerate drug safety research. Banda JM; Evans L; Vanguri RS; Tatonetti NP; Ryan PB; Shah NH Sci Data; 2016 May; 3():160026. PubMed ID: 27193236 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]